Chilton Capital Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.14M Sell
7,290
-2
-0% -$300 0.04% 123
2026
Q1
$1.11M Sell
7,292
-597
-8% -$91.5K 0.04% 123
2025
Q4
$1.09M Sell
7,889
-731
-8% -$95.7K 0.04% 125
2025
Q3
$1.11M Sell
8,620
-1,210
-12% -$148K 0.04% 132
2025
Q2
$1.19M Sell
9,830
-72
-0.7% -$8.12K 0.04% 123
2025
Q1
$1.1M Sell
9,902
-385
-4% -$41K 0.05% 121
2024
Q4
$1M Sell
10,287
-413
-4% -$44K 0.04% 129
2024
Q3
$1.23M Sell
10,700
-70
-0.6% -$7.94K 0.05% 123
2024
Q2
$1.15M Sell
10,770
-618
-5% -$62K 0.05% 123
2024
Q1
$1.1M Buy
11,388
+708
+7% +$72.6K 0.05% 123
2023
Q4
$1.08M Sell
10,680
-10
-0.1% -$965 0.05% 125
2023
Q3
$1.09M Sell
10,690
-53
-0.5% -$5.38K 0.06% 117
2023
Q2
$1.08M Sell
10,743
-32
-0.3% -$3.2K 0.06% 121
2023
Q1
$991K Sell
10,775
-917
-8% -$80.1K 0.06% 122
2022
Q4
$1.06M Buy
11,692
+191
+2% +$16.1K 0.07% 125
2022
Q3
$874K Buy
11,501
+1,167
+11% +$96.7K 0.06% 127
2022
Q2
$874K Sell
10,334
-92
-0.9% -$8.07K 0.05% 130
2022
Q1
$914K Buy
10,426
+2,265
+28% +$196K 0.05% 133
2021
Q4
$714K Sell
8,161
-410
-5% -$34K 0.04% 148
2021
Q3
$701K Buy
8,571
+1,649
+24% +$148K 0.04% 145
2021
Q2
$632K Sell
6,922
-135,564
-95% -$12.1M 0.04% 147
2021
Q1
$12.2M Sell
142,486
-8,368
-6% -$751K 0.81% 56
2020
Q4
$14.2M Sell
150,854
-144
-0.1% -$12.6K 1.02% 47
2020
Q3
$13.1M Buy
150,998
+10,200
+7% +$884K 1.02% 39
2020
Q2
$12.3M Buy
140,798
+5,612
+4% +$484K 1.05% 40
2020
Q1
$11.1M Buy
135,186
+4,654
+4% +$415K 1.12% 34
2019
Q4
$12.4M Sell
130,532
-466
-0.4% -$41.8K 0.98% 48
2019
Q3
$11.4M Buy
130,998
+286
+0.2% +$25.7K 0.94% 52
2019
Q2
$11.9M Sell
130,712
-16,977
-11% -$1.44M 1.02% 45
2019
Q1
$12.7M Buy
147,689
+2,448
+2% +$197K 1.13% 34
2018
Q4
$11.2M Buy
145,241
+4,600
+3% +$358K 1.08% 33
2018
Q3
$10.9M Sell
140,641
-2,435
-2% -$180K 0.9% 48
2018
Q2
$9.67M Buy
143,076
+2,823
+2% +$195K 0.83% 58
2018
Q1
$10.1M Buy
140,253
+135,488
+2,843% +$10.3M 0.92% 51
2017
Q4
$359K Buy
4,765
+304
+7% +$22.9K 0.03% 147
2017
Q3
$343K Sell
4,461
-39
-0.9% -$2.94K 0.03% 141
2017
Q2
$337K Sell
4,500
-77,491
-95% -$5.49M 0.04% 131
2017
Q1
$5.46M Sell
81,991
-3,641
-4% -$243K 0.54% 68
2016
Q4
$5.59M Sell
85,632
-9,580
-10% -$621K 0.58% 65
2016
Q3
$6.74M Sell
95,212
-4,152
-4% -$303K 0.68% 60
2016
Q2
$7.35M Sell
99,364
-2,881
-3% -$199K 0.71% 59
2016
Q1
$6.64M Sell
102,245
-7,799
-7% -$531K 0.66% 63
2015
Q4
$8.48M Buy
110,044
+2,238
+2% +$178K 0.89% 42
2015
Q3
$8.88M Sell
107,806
-11,918
-10% -$1.06M 0.91% 45
2015
Q2
$10.6M Buy
119,724
+1,456
+1% +$134K 0.99% 37
2015
Q1
$10.4M Sell
118,268
-6,663
-5% -$591K 1.05% 36
2014
Q4
$10.4M Sell
124,931
-5,816
-4% -$482K 1.05% 34
2014
Q3
$11M Buy
130,747
+1,555
+1% +$126K 1.17% 28
2014
Q2
$10.5M Buy
129,192
+3,131
+2% +$246K 1.02% 37
2014
Q1
$9.6M Buy
126,061
+3,750
+3% +$273K 1.01% 38
2013
Q4
$8.81M Buy
122,311
+30,349
+33% +$2.11M 0.95% 39
2013
Q3
$6.32M Sell
91,962
-833
-0.9% -$55.1K 0.72% 52
2013
Q2
$5.88M Buy
+92,795
New +$6.04M 0.73% 53

Other funds holding NVS

Chilton Capital Management's NVS Position: Q2 2026 in Review

Chilton Capital Management reduced its Novartis (NVS) stake by 0.03% in Q2 2026, selling an estimated $300 and leaving 7,290 shares worth $1.14M. The position accounts for 0.04% of the portfolio, ranked #123.

Chilton Capital Management first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $14.2M in Q4 2020. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Chilton Capital Management held 7,290 shares of Novartis worth $1.14M as of Q2 2026.
  • Chilton Capital Management sold 2 Novartis shares in Q2 2026, an estimated $300.
  • Novartis made up 0.04% of Chilton Capital Management's portfolio in Q2 2026, its #123 holding.
  • Chilton Capital Management first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Chilton Capital Management's Novartis position peaked at $14.2M in Q4 2020.
  • 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.